Clinical endocrinology · 2026
Sex- and Age-Specific Metabolic Outcomes of Prolactin Normalisation in Hyperprolactinaemia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Iglesias Pedro, Rodríguez María Dolores Moure, Guerrero-Pérez Fernando, Simó-Servat Andreu, Fernández Laura González, Fernández-Rodríguez Eva, Castro Patricia Pérez, Villar-Taibo Rocío, Biagetti Betina, Orois Aida, Donato Sara de Miranda Lemos, Lázaro Victoria Alcázar, Roig-Marín Noel, Serra Guillermo, Civantos Soralla, Rivero Gonzalo, de Araoz Carmen María Fernandez, de Paz Isabel Pavón, Outeiriño-Blanco Elena, Cordido Fernando, Centeno Rogelio García, Araujo-Castro Marta, Lamas Cristina, Paja Miguel, Hanzu Felicia Alexandra, Díez Juan J
Аннотация
BACKGROUND: Hyperprolactinaemia has been linked to adverse metabolic profiles, but the metabolic consequences of prolactin (PRL) normalisation remain insufficiently characterised.
OBJECTIVE: To evaluate changes in anthropometric, blood pressure, and metabolic parameters following PRL normalisation, with analyses stratified by sex and age.
METHODS: We retrospectively analysed 445 patients (286 women, 159 men) treated with cabergoline who had paired clinical and biochemical measurements before and after PRL normalisation. Pre-post differences were assessed overall and stratified by sex and age (< 50 vs. ≥ 50 years). Additional multivariable models examined independent predictors of metabolic changes.
RESULTS: Men exhibited more severe baseline disease, including higher PRL levels, greater prevalence of macroadenomas, hypopituitarism, and cardiometabolic comorbidities. After PRL normalisation, body weight, BMI, and blood pressure showed no clinically relevant changes. Small but statistically significant reductions were observed in total cholesterol (185 → 181 mg/dL; p < 0.001), LDL-C (110 → 106 mg/dL; p = 0.038), and triglycerides (91 → 82 mg/dL; p < 0.001). These lipid changes, however, were not independently explained by sex, age, PRL dynamics, cabergoline exposure, or gonadal status in multivariable analyses. Fasting glucose and HDL-C remained largely unchanged. By contrast, the TyG index decreased significantly across sexes and age groups, and multivariable modelling identified higher initial cabergoline dose and baseline hypogonadism as independent determinants of greater TyG reduction.
CONCLUSIONS: PRL normalisation with cabergoline was associated with modest improvements in conventional lipid fractions and a more consistent reduction in the TyG index, suggesting a preferential impact on insulin-resistance-related pathways. The absence of independent effects of sex, age, PRL dynamics, or cabergoline exposure on lipid changes underscores the need for cautious interpretation of statistically significant but small absolute shifts.
OBJECTIVE: To evaluate changes in anthropometric, blood pressure, and metabolic parameters following PRL normalisation, with analyses stratified by sex and age.
METHODS: We retrospectively analysed 445 patients (286 women, 159 men) treated with cabergoline who had paired clinical and biochemical measurements before and after PRL normalisation. Pre-post differences were assessed overall and stratified by sex and age (< 50 vs. ≥ 50 years). Additional multivariable models examined independent predictors of metabolic changes.
RESULTS: Men exhibited more severe baseline disease, including higher PRL levels, greater prevalence of macroadenomas, hypopituitarism, and cardiometabolic comorbidities. After PRL normalisation, body weight, BMI, and blood pressure showed no clinically relevant changes. Small but statistically significant reductions were observed in total cholesterol (185 → 181 mg/dL; p < 0.001), LDL-C (110 → 106 mg/dL; p = 0.038), and triglycerides (91 → 82 mg/dL; p < 0.001). These lipid changes, however, were not independently explained by sex, age, PRL dynamics, cabergoline exposure, or gonadal status in multivariable analyses. Fasting glucose and HDL-C remained largely unchanged. By contrast, the TyG index decreased significantly across sexes and age groups, and multivariable modelling identified higher initial cabergoline dose and baseline hypogonadism as independent determinants of greater TyG reduction.
CONCLUSIONS: PRL normalisation with cabergoline was associated with modest improvements in conventional lipid fractions and a more consistent reduction in the TyG index, suggesting a preferential impact on insulin-resistance-related pathways. The absence of independent effects of sex, age, PRL dynamics, or cabergoline exposure on lipid changes underscores the need for cautious interpretation of statistically significant but small absolute shifts.